CN110225752B - 用作gpr120调节器的单环化合物 - Google Patents

用作gpr120调节器的单环化合物 Download PDF

Info

Publication number
CN110225752B
CN110225752B CN201780068713.3A CN201780068713A CN110225752B CN 110225752 B CN110225752 B CN 110225752B CN 201780068713 A CN201780068713 A CN 201780068713A CN 110225752 B CN110225752 B CN 110225752B
Authority
CN
China
Prior art keywords
compound
preparation
lcms
esi
nmr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780068713.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN110225752A (zh
Inventor
布里安·雷蒙多
埃莱娜·S·科尔通
约翰·格里芬
埃里克·施坦格兰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Overall Health
Original Assignee
Overall Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Overall Health filed Critical Overall Health
Publication of CN110225752A publication Critical patent/CN110225752A/zh
Application granted granted Critical
Publication of CN110225752B publication Critical patent/CN110225752B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201780068713.3A 2016-09-12 2017-09-11 用作gpr120调节器的单环化合物 Active CN110225752B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662393616P 2016-09-12 2016-09-12
US62/393,616 2016-09-12
PCT/US2017/050956 WO2018049324A1 (en) 2016-09-12 2017-09-11 Monocyclic compounds useful as gpr120 modulators

Publications (2)

Publication Number Publication Date
CN110225752A CN110225752A (zh) 2019-09-10
CN110225752B true CN110225752B (zh) 2023-05-05

Family

ID=61562455

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780068713.3A Active CN110225752B (zh) 2016-09-12 2017-09-11 用作gpr120调节器的单环化合物

Country Status (7)

Country Link
US (3) US10800773B2 (enExample)
EP (1) EP3509587B1 (enExample)
JP (1) JP7086942B2 (enExample)
KR (1) KR102537985B1 (enExample)
CN (1) CN110225752B (enExample)
CA (1) CA3041033A1 (enExample)
WO (1) WO2018049324A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110225752B (zh) * 2016-09-12 2023-05-05 整体健康 用作gpr120调节器的单环化合物
CA3041038A1 (en) * 2016-09-12 2018-03-15 Numerate, Inc. Bicyclic compounds useful as gpr120 modulators
EP3781146A4 (en) * 2018-04-20 2022-01-26 Krish Biotech Research Private Limited Method of treatment of non-alcoholic steatohepatitis, nash
US11142525B2 (en) * 2018-11-15 2021-10-12 Pfizer Inc. Azalactam compounds as HPK1 inhibitors
CA3181415A1 (en) 2020-05-01 2021-11-04 Pfizer Inc. Azalactam compounds as hpk1 inhibitors
BR112022022551A2 (pt) * 2020-05-08 2023-01-17 Georgiamune Llc Moduladores de akt3
CN114671827B (zh) * 2020-12-24 2024-09-20 杭州百新生物医药科技有限公司 邻苯甲酰磺酰亚胺类衍生物及其应用
KR102605163B1 (ko) * 2021-06-01 2023-11-23 연세대학교 산학협력단 뇌암의 예방 또는 치료용 조성물

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110312976A1 (en) * 2009-03-11 2011-12-22 Msd K.K. Novel isoindolin-1-one derivative
JP2014533736A (ja) * 2011-11-30 2014-12-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 新規二環式ジヒドロイソキノリン−１−オン誘導体
WO2014209034A1 (en) * 2013-06-27 2014-12-31 Lg Life Sciences Ltd. Biaryl derivatives as gpr120 agonists
US20150274672A1 (en) * 2012-10-11 2015-10-01 Merck Sharp & Dohme Corp. Substituted spiropiperidinyl compounds useful as gpr120 agonists
JP2016141618A (ja) * 2015-01-29 2016-08-08 国立大学法人金沢大学 脱水縮合剤

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2735225A (en) * 1956-02-21 Table ix p petri dish tests with x-phthalimido-
DE2253251A1 (de) 1972-10-30 1974-05-09 Thomae Gmbh Dr K Neue phthalimido-sulfonylharnstoffe
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US4165435A (en) * 1976-06-25 1979-08-21 Ciba-Geigy Corporation Fire retardant s-triazine derivatives
EP0145078B1 (en) 1983-12-02 1988-10-12 Shell Internationale Researchmaatschappij B.V. Diphenyl ether herbicides
FR2659327A1 (fr) 1990-03-08 1991-09-13 Centre Nat Rech Scient Derives du benzisothiazolinone-1-dioxyde, utilisables comme inhibiteurs des elastases.
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5350761A (en) 1991-07-30 1994-09-27 Ciba-Geigy Corporation Indolyl substituted hydroxylamine derivatives
ES2111059T3 (es) 1991-07-30 1998-03-01 Ciba Geigy Ag Derivados de hidroxilamina substituidos con heteroarilo como inhibidores de lipoxigenasa.
TW219935B (enExample) 1991-12-25 1994-02-01 Mitsubishi Chemicals Co Ltd
CA2250372C (en) * 1996-03-29 2005-06-21 Pfizer Inc. 6-phenylpyridyl-2-amine derivatives
US6716836B2 (en) 2001-03-22 2004-04-06 Boehringer Ingelheim (Canada) Ltd. Non-nucleoside reverse transcriptase inhibitors
GB0124627D0 (en) 2001-10-15 2001-12-05 Smithkline Beecham Plc Novel compounds
DE10348022A1 (de) 2003-10-15 2005-05-25 Imtm Gmbh Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
CA2547430A1 (en) 2003-11-26 2005-06-09 Takeda Pharmaceutical Company Limited Receptor function regulating agent
TW200613272A (en) 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
WO2006038594A1 (ja) 2004-10-04 2006-04-13 Ono Pharmaceutical Co., Ltd. Ｎ型カルシウムチャネル阻害薬
US8110681B2 (en) 2006-03-17 2012-02-07 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compounds for the treatment of spinal muscular atrophy and other uses
EP2098517B1 (en) 2006-12-01 2013-12-18 Msd K.K. Novel phenyl-isoxazol-3-ol derivative
KR101517154B1 (ko) 2006-12-27 2015-04-30 사노피 Ｒｈｏ-키나제의 억제제로서의 치환된 이소퀴놀린 및 이소퀴놀리논 유도체
EA200901099A1 (ru) 2007-02-22 2010-04-30 Айрм Ллк Соединения и способы модулирования сопряженных с g-белком рецепторов
EA200901098A1 (ru) 2007-02-22 2010-04-30 Айрм Ллк Производные тиазола в качестве модуляторов сопряженных с g-белком рецепторов
JP5420400B2 (ja) 2007-04-26 2014-02-19 国立大学法人京都大学 Ｇタンパク質共役型レセプター作動剤
EP2172198B1 (en) 2007-07-20 2014-04-16 Chugai Seiyaku Kabushiki Kaisha p27 PROTEIN INDUCER
CA2725316A1 (en) 2008-06-02 2009-12-10 Banyu Pharmaceutical Co., Ltd. Novel isoxazole derivative
UA107917C2 (ru) 2008-10-21 2015-03-10 Сімабей Терапьютікс, Інк. Арильный агонист рецептора gpr120 и его применение
AR074760A1 (es) 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
US8314120B2 (en) 2010-03-30 2012-11-20 Abbott Gmbh & Co. Kg Small molecule potentiators of metabotropic glutamate receptors
JP5746334B2 (ja) 2010-06-16 2015-07-08 シマベイ セラピューティクス， インコーポレーテッド Ｇｐｒ１２０受容体作動薬及びその使用
US8299117B2 (en) 2010-06-16 2012-10-30 Metabolex Inc. GPR120 receptor agonists and uses thereof
CA2841757A1 (en) * 2011-07-15 2013-01-24 Etzer Darout Gpr 119 modulators
WO2013139341A1 (en) 2012-03-20 2013-09-26 Syddansk Universitet Gpr120 receptor modulators
KR101942752B1 (ko) 2012-11-05 2019-01-28 주식회사 엘지화학 Ｇｐｒ120 효능제로서의 티오아릴 유도체
CA2893239A1 (en) 2012-12-03 2014-06-12 F. Hoffmann-La Roche Ag Substituted triazole and imidazole compounds
US9714252B2 (en) 2012-12-20 2017-07-25 Purdue Pharma L.P. Cyclic sulfonamides as sodium channel blockers
US8962660B2 (en) 2013-03-14 2015-02-24 Bristol-Myers Squibb Company Oxabicyclo [2.2.2] acid GPR120 modulators
WO2014149987A1 (en) 2013-03-14 2014-09-25 Janssen Pharmaceutica Nv Bicyclic pyrrole derivatives useful as agonists of gpr120
CN105209444B (zh) 2013-03-14 2017-12-29 詹森药业有限公司 可用作gpr120的激动剂的苯并稠合杂环衍生物
SG11201506796XA (en) 2013-03-14 2015-09-29 Bristol Myers Squibb Co Bicyclo [2.2.1] acid gpr120 modulators
ES2690145T3 (es) 2013-03-14 2018-11-19 Janssen Pharmaceutica Nv Agonistas de GPR120 para el tratamiento de diabetes de tipo 2
TW201623286A (zh) * 2014-04-04 2016-07-01 賽諾菲公司 作為ｇｐｒ１１９調控劑用於治療糖尿病、肥胖、血脂異常及相關病症之異吲哚啉酮化合物
BR112016024936A2 (pt) 2014-05-07 2017-08-15 Bristol Myers Squibb Co moduladores de gpr40 à base de pirrolidina para tratamento de doenças como diabetes
CN107074817B (zh) 2014-08-29 2023-12-15 Chdi基金会股份有限公司 用于成像亨廷顿蛋白的探针
EP3365334B1 (en) 2015-10-21 2024-07-17 Otsuka Pharmaceutical Co., Ltd. Benzolactam compounds as protein kinase inhibitors
CN110225752B (zh) * 2016-09-12 2023-05-05 整体健康 用作gpr120调节器的单环化合物
CA3041038A1 (en) 2016-09-12 2018-03-15 Numerate, Inc. Bicyclic compounds useful as gpr120 modulators

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110312976A1 (en) * 2009-03-11 2011-12-22 Msd K.K. Novel isoindolin-1-one derivative
JP2014533736A (ja) * 2011-11-30 2014-12-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 新規二環式ジヒドロイソキノリン−１−オン誘導体
US20150274672A1 (en) * 2012-10-11 2015-10-01 Merck Sharp & Dohme Corp. Substituted spiropiperidinyl compounds useful as gpr120 agonists
WO2014209034A1 (en) * 2013-06-27 2014-12-31 Lg Life Sciences Ltd. Biaryl derivatives as gpr120 agonists
JP2016141618A (ja) * 2015-01-29 2016-08-08 国立大学法人金沢大学 脱水縮合剤

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"Synthesis and structural investigation of N-pyridyl-1, 3-dihydroxyisoindolines";Jasim Al-Rawi等;《Asian Journal of Chemistry》;19910131;第3卷(第1期);第30-37页，尤其是第30-31页化合物2部分 *
"Trisubstituted Pyrimidines as Efficacious and Fast-Acting Antimalarials";Neil R. Norcross等;《Journal of Medicinal Chemistry》;20160617;第6101-6120页，尤其是 *
RN：1334634-35-3;CHEMICAL ABSTRACTS SERVICE;《STN Registry数据库》;20111007 *
RN：1440520-62-6;CHEMICAL ABSTRACTS SERVICE;《STN Registry数据库》;20130624 *
RN：1935530-23-6;CHEMICAL ABSTRACTS SERVICE;《STN Registry数据库》;20160620 *

Also Published As

Publication number Publication date
EP3509587A1 (en) 2019-07-17
KR20190067174A (ko) 2019-06-14
CA3041033A1 (en) 2018-03-15
KR102537985B1 (ko) 2023-05-30
US11548886B2 (en) 2023-01-10
CN110225752A (zh) 2019-09-10
JP7086942B2 (ja) 2022-06-20
US12116362B2 (en) 2024-10-15
EP3509587A4 (en) 2020-03-11
US20190202821A1 (en) 2019-07-04
US20210101896A1 (en) 2021-04-08
US20230183231A1 (en) 2023-06-15
EP3509587C0 (en) 2023-12-06
WO2018049324A1 (en) 2018-03-15
JP2019530674A (ja) 2019-10-24
EP3509587B1 (en) 2023-12-06
US10800773B2 (en) 2020-10-13

Similar Documents

Publication Publication Date Title
CN110225752B (zh) 用作gpr120调节器的单环化合物
US11919891B2 (en) Bicyclic compounds useful as GPR120 modulators
US11447453B2 (en) Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof
JP4667867B2 (ja) 置換フロ［２，３−ｂ］ピリジン誘導体
US20070149547A1 (en) Bipyridyl amides as modulators of metabotropic glutamate receptor-5
JP2009533410A (ja) Ｇタンパク質共役型受容体（ｇｐｒ１１９）アゴニストとしてのアゼチジン誘導体
US10369146B2 (en) Phenyl linked quinolinyl modulators of RORγt
JP4092732B2 (ja) ブラジキニン作動薬としてのキノリンおよびベンズイミダゾール誘導体
CN116438174B (zh) 化合物及其作为mif抑制剂的用途
AU2007332867A1 (en) Substituted diazepine sulfonamides as bombesin receptor subtype-3 modulators
HK40005332B (en) Monocyclic compounds useful as gpr120 modulators
HK40005332A (en) Monocyclic compounds useful as gpr120 modulators
HK40005335B (en) Bicyclic compounds useful as gpr120 modulators
HK40005335A (en) Bicyclic compounds useful as gpr120 modulators

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20200909

Address after: Massachusetts, USA

Applicant after: Overall health

Address before: California, USA

Applicant before: NUMERATE, Inc.

GR01 Patent grant
GR01 Patent grant